Regulatory
CRN calls on Congress to clarify FDA’s authority over dietary supplements in the FD&C Act
April 30th 2021The Council for Responsible Nutrition is calling on Congress to address an unintended “loophole” in the Food, Drug, and Cosmetic Act (FD&C Act) that casts doubt on the legal authority of the U.S. Food and Drug Administration (FDA) to regulate products that do not mee the strict definition of “dietary supplement” in the statute.
Fast-moving bill in California sets “dangerous precedent” for consumer access to dietary supplements
April 20th 2021Last week, California’s Assembly Health Committee voted to ban sales of weight-loss dietary supplements to minors. The bill is headed for another round of votes and could ultimately be signed into law.
Bio-Cat Microbials announced GRAS status of its Opti-Biome probiotic strain
April 20th 2021Bio-Cat Microbials LLC has received a “Letter of No Objection” from the U.S. Food and Drug Administration (FDA) regarding the company’s GRAS (generally recognized as safe) notice for its Opti-Biome Bacillus subtilis MB40 probiotic.
Verdure Sciences’ turmeric ingredient, Longvida receives ANVISA approval
April 19th 2021Verdure Sciences launched Longvida, a turmeric extract standardized to curcumin and total curcuminoids (solid lipid curcumin particle - SLCP), in Brazil after receiving ANVISA approval through distribution partner Kilyos Nutrition
CV Sciences, Alkemist Labs partner to support NIST’s cannabis QA program
April 14th 2021CV Sciences, Inc. formed an ongoing partnership with Alkemist Labs to collaborate with the National Institute of Standards and Technology (NIST) on efforts to help cannabis testing labs demonstrate and improve measurement capabilities and comparability.
Study from NSF finds illegal stimulants in sports nutrition and weight management products
March 24th 2021A recent study conducted by NSF International and Harvard Medical School found nine prohibited stimulants in 17 sports and weight loss supplements on top of the illegal Deterenol already on the label.
FDA sends warning letters to companies selling topical pain relief products with CBD
March 22nd 2021FDA explained in its warning letters to the firms that even if CBD in the product was labeled as an inactive ingredient, the product cannot be legally marketed without an approved new drug application.